Loading…
Multiple Site Hydrogen Isotope Labelling of Pharmaceuticals
Radiolabelling is fundamental in drug discovery and development as it is mandatory for preclinical ADME studies and late‐stage human clinical trials. Herein, a general, effective, and easy to implement method for the multiple site incorporation of deuterium and tritium atoms using the commercially a...
Saved in:
Published in: | Angewandte Chemie International Edition 2020-11, Vol.59 (47), p.21114-21120 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Radiolabelling is fundamental in drug discovery and development as it is mandatory for preclinical ADME studies and late‐stage human clinical trials. Herein, a general, effective, and easy to implement method for the multiple site incorporation of deuterium and tritium atoms using the commercially available and air‐stable iridium precatalyst [Ir(COD)(OMe)]2 is described. A large scope of pharmaceutically relevant substructures can be labelled using this method including pyridine, pyrazine, indole, carbazole, aniline, oxa‐/thia‐zoles, thiophene, but also electron‐rich phenyl groups. The high functional group tolerance of the reaction is highlighted by the labelling of a wide range of complex pharmaceuticals, containing notably halogen or sulfur atoms and nitrile groups. The multiple site hydrogen isotope incorporation has been explained by the in situ formation of complementary catalytically active species: monometallic iridium complexes and iridium nanoparticles.
A general method for the multiple site hydrogen isotope labelling of complex molecules using the commercially available and air‐stable iridium precatalyst [Ir(COD)(OMe)]2 is reported. This new synthetic method possesses multiple key features far beyond the state‐of‐the‐art methods for tritium labelling, including a very broad substrate scope and an exceptional functional group tolerance facilitating the access to complex pharmaceuticals with high molar activities. |
---|---|
ISSN: | 1433-7851 1521-3773 |
DOI: | 10.1002/anie.202008519 |